Testing ML-007C-MA for Alzheimer's Psychosis
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a study drug called ML-007C-MA to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease who also have psychosis. If you or your loved one has Alzheimer's and has been experiencing false beliefs or seeing/hearing things that aren't there for at least two months, this study may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have possible or probable Alzheimer's disease as diagnosed by a doctor.
- You must have had psychotic symptoms, like hallucinations or delusions, for at least 2 months before starting the study.
- You must be living at the same home or facility for at least 6 weeks before screening, and have a caregiver who can report on your symptoms.
- Your hallucinations or delusions must be moderate to severe based on specific rating scales.
- You must score between 6 and 26 on a standard memory test (MMSE).
- You cannot have other major medical or psychiatric conditions that could explain the psychosis, such as substance abuse or a recent major depression.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.
This trial tests a long-term treatment (ML-007C-MA) for people with Alzheimer's disease who have psychosis. It is for those who already completed an earlier study with the same drug and may benefit from continuing it. The goal is to see if ongoing treatment is helpful and safe.
This trial tests an experimental drug, ITI-1284, to see if it can safely reduce psychosis (hallucinations or delusions) in people with Alzheimer's disease. It may be an option for patients who have both Alzheimer's and related psychotic symptoms.
This trial tests a new drug called KarXT to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. If you or a loved one has Alzheimer's and experiences these symptoms, this study might offer a new treatment option.
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Hear when a new Psychosis Associated With Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.